Evidence map›Paper›PMID 34645608›Full record

ArticleCancer research2021

Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression.

Annalisa Saltari, Andreas Dzung, Marika Quadri, Natascia Tiso, Nicola Facchinello, Alberto Hernández-Barranco, Susana Garcia-Silva, Laura Nogués, Corinne Isabelle Stoffel, Phil F Cheng and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. p53 Family in Resistance to Targeted Therapy of Melanoma.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Annalisa SaltariDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-8621-4039
Andreas DzungDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-1776-1928
Marika QuadriLaboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID https://orcid.org/0000-0001-7619-660X
Natascia TisoLaboratory of Developmental Genetics, Department of Biology University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0002-5444-9853
Nicola FacchinelloLaboratory of Developmental Genetics, Department of Biology University of Padova, Padova, Italy.
Alberto Hernández-BarrancoMicroenvironment and Metastasis Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Center (CNIO), Madrid, Spain.ORCID https://orcid.org/0000-0002-1590-5107
Susana Garcia-SilvaMicroenvironment and Metastasis Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Center (CNIO), Madrid, Spain.ORCID https://orcid.org/0000-0003-1065-0245
Laura NoguésMicroenvironment and Metastasis Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Corinne Isabelle StoffelDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland.
Phil F ChengDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-2940-006X
Patrick TurkoDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0003-3695-8264
Ossia M EichhoffDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-3319-1312
Francesca TruzziLaboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Alessandra MarconiLaboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID https://orcid.org/0000-0002-5667-5766
Carlo PincelliLaboratory of Cutaneous Biology, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.ORCID https://orcid.org/0000-0003-4416-2637
Héctor PeinadoMicroenvironment and Metastasis Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Center (CNIO), Madrid, Spain.ORCID https://orcid.org/0000-0002-4256-3413
Reinhard DummerDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-2279-6906
Mitchell P LevesqueDepartment of Dermatology, University of Zurich Hospital, University of Zurich, Zurich, Switzerland. mitchell.levesque@usz.ch.
University Hospital of Zurich · CHSpanish National Cancer Research Centre · ESUniversity of Modena and Reggio Emilia · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD271 (NGFR) is a neurotrophin receptor that belongs to the tumor necrosis receptor (TNFR) family. Upon ligand binding, CD271 can mediate either survival or cell death. Although the role of CD271 as a marker of tumor-initiating cells is still a matter of debate, its role in melanoma progression has been well documented. Moreover, CD271 has been shown to be upregulated after exposure to both chemotherapy and targeted therapy. In this study, we demonstrate that activation of CD271 by a short β-amyloid-derived peptide (Aβ

Indexed as

Molecular Targeted TherapyAmyloid beta-PeptidesAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell ProliferationDrug Therapy, CombinationFemaleGene Expression Regulation, NeoplasticHumansMelanomaMiceMice, NudeNerve Tissue ProteinsReceptors, Nerve Growth FactorTumor Cells, CulturedAmyloid beta-PeptidesNerve Tissue ProteinsNGFR protein, humanReceptors, Nerve Growth Factor

Identifiers

PMID34645608
PMCPMC9397645
OpenAlexW3206768523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.